Alemtuzumab for Multiple Sclerosis

被引：0
作者：
Mark D. Willis
Neil P. Robertson
机构：
[1] Cardiff University,Institute of Psychological Medicine and Clinical Neuroscience, University Hospital of Wales
来源：
Current Neurology and Neuroscience Reports | 2016年 / 16卷
关键词：
Multiple sclerosis; Alemtuzumab; Autoimmunity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Alemtuzumab is a humanised anti-CD52 monoclonal antibody approved for use in active, relapsing multiple sclerosis (MS). Administration results in a rapid depletion of circulating lymphocytes with a subsequent beneficial immune reconstitution. Early open-label experience and recent clinical trials have demonstrated a dramatic effect on relapse rates as well as a positive effect on radiological disease outcomes and disability measures. Despite a mechanism of action that results in profound lymphopaenia, opportunistic infections are rarely seen and no excess association with malignancy has been identified. However, acquired autoimmune disease (AID) is a common adverse event following treatment, necessitating rigorous monitoring in order to facilitate prompt detection and management. Despite this issue, a unique dosing schedule and durability of effect make alemtuzumab a welcome addition to currently available treatment options for MS.
引用
收藏
相关论文
共 152 条
[1]  
Compston A(2008)Multiple sclerosis Lancet 372 1502-17
[2]  
Coles A(2011)Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis Nature 476 214-9
[3]  
Sawcer S(2013)Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects PLoS Genet 9 e1003926-21
[4]  
Hellenthal G(2016)Novel agents for relapsing forms of multiple sclerosis Annu Rev Med 67 309-304
[5]  
Pirinen M(1999)Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis Ann Neurol 46 296-301
[6]  
Patsopoulos NA(1994)Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis Lancet 344 298-1828
[7]  
Barcellos LF(2012)Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial Lancet 380 1819-1839
[8]  
Hintzen RQ(2012)Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial Lancet 380 1829-801
[9]  
Straus Farber R(2008)Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis N Engl J Med 359 1786-108
[10]  
Harel A(2006)The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy J Neurol 253 98-37
12345678910